Antihypertensive Drugs Market is Estimated to Rise at a CAGR of 3% during the Forecast Period, observes TMR Study – QNT Press Release


  • The global antihypertensive drugs market is likely to be driven by the introduction of novel drug/therapeutic compounds with disease-modifying capabilities and better effectiveness
  • North America’s considerable market share is due to high uptake of antihypertensive medications in the US and an increasing number of new drug approvals by the US FDA

ALBANY, NY, June 15, 2022 /PRNewswire/ — The revenue of antihypertensive drugs market stood at US$ 30.2 Bn in 2021. The global market is likely to develop at a CAGR of 3% during the forecast period, from 2022 to 2031. The global antihypertensive drugs market is likely to attain a valuation of US$ 40 Bn by 2031. The global antihypertensive drugs market is anticipated to be propelled by a rise in the launch of novel pharmaceuticals and diagnostic agents. Besides, major industrial advancements such as partnerships and set-up of R&D facilities are also expected to fuel antihypertensive drugs market expansion. The global market is expected to be driven by rising disposable income as well as the introduction of innovative disease-modifying treatments during the forecast period. Firms in the antihypertensive drugs industry are projected to benefit from significant expansion in telemedicine and e-Health applications in the long run.

In order to meet treatment objectives, most patients need a mix of antihypertensive medications. In an effort to boost efficacy of the first drug, combination therapy involves adding some other family of blood pressure medication to it. There is a significant unmet need for antihypertensive hypertension medications, indicating a shortage of viable products. This creates a huge opportunity for new market entrants to profit from unmet demands, owing to patient non-compliance or poor compliance with already existing medicines.

Antihypertensive drug trends in stroke patients could reveal critical insights into secondary prevention gaps that are likely to help guide future treatments. In order to acquire a competitive advantage over other market participants, healthcare businesses are strengthening R&D in the fields of resistant hypertension therapy and genomics.

Request Brochure of Antihypertensive Drugs Market Research Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7718

Key Findings of Market Report

  • Innovative antihypertensive medications and pharmacological treatments, which successfully target illness progression, are predicted to have promising benefits. Novel medicines for disorders such as calcium channel blockers (CCB), angiotensin converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers (ARBs) are projected to transform the existing picture in the global antihypertensive …

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center